Literature DB >> 24715008

Sweetened beverages intake, hyperuricemia and metabolic syndrome: the Mexico City Diabetes Study.

Rubén López-Molina1, Socorro Parra-Cabrera1, Ruy López-Ridaura1, María E González-Villalpando, Ele Ferrannini2, Clicerio González-Villalpando.   

Abstract

OBJECTIVE. To determine prevalence of hyperuricemia and its relation with intake of sweetened beverages (SB) and metabolic syndrome (MS) in low income urban Mexican population. MATERIALS AND METHODS. A cross-sectional analysis of The Mexico City Diabetes Study, a prospective population-based investigation (1 173 participants) was performed. We used logistic regression, adjusted by pertinent variables. We determined prevalence of hyperuricemia and explored associations of uric acid levels with MS and intake of SB. RESULTS. Prevalence of hyperuricemia was 26.5 and 19.8% in males and females respectively. In an adjusted multivariate model, body mass index, waist circumference, and triglyceride were higher as uric acid quartiles increased (p<0.005-0.001). The odds ratio for MS was 1.48 for 3rd uric acid quartile and 2.03 for 4th quartile. Higher consumption of SB was associated with higher uric acid levels (p<0.001). CONCLUSION. Prevalence of hyperuricemia is high. Potential association with intake of SB, resulting in metabolic alterations should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24715008     DOI: 10.21149/spm.v55i6.7301

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  2 in total

1.  Did high sugar-sweetened beverage purchasers respond differently to the excise tax on sugar-sweetened beverages in Mexico?

Authors:  Shu Wen Ng; Juan A Rivera; Barry M Popkin; M Arantxa Colchero
Journal:  Public Health Nutr       Date:  2018-12-18       Impact factor: 4.022

2.  Positively increased visceral adiposity index in hyperuricemia free of metabolic syndrome.

Authors:  Dongfeng Gu; Yanan Ding; Yunfeng Zhao; Shuzhai Miao; Qingshan Qu
Journal:  Lipids Health Dis       Date:  2018-05-07       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.